循环肿瘤细胞：好的、坏的和丑陋的。
Circulating tumour cells: The Good, the Bad and the Ugly.
发表日期：2023 Feb 15
作者：
Mark Bates, Bashir M Mohamed, Mark P Ward, Tanya E Kelly, Roisin O'Connor, Victoria Malone, Robert Brooks, Doug Brooks, Stavros Selemidis, Cara Martin, Sharon O'Toole, John J O'Leary
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
摘要：
这篇评论是关于循环肿瘤细胞（CTCs）的现有认识的概述，它们可能是最致命的癌细胞类型，也可能是转移级联反应的关键组成部分。CTCs的临床功用（所谓的“好”）包括它们的诊断、预后和治疗潜力。相反，它们的复杂生物学（所谓的“坏”），包括CD45+/EpCAM+ CTCs的存在，加剧了它们的分离和鉴定，进而妨碍了它们临床转化。CTCs能够形成由非离散表型群体（如间充质型CTCs）和同异型群集组成的微小栓子，这些群集准备与循环中的其他细胞相互作用，包括免疫细胞和血小板，这可能增加它们的恶性潜力。这些微小栓子（所谓的“丑”）代表了一个预后重要的CTC子集，然而，表型EMT/MET梯度给已经充满挑战的情况增添了更多复杂因素。版权所有©2023作者。由Elsevier B.V.出版。保留所有权利。
This review is an overview of the current knowledge regarding circulating tumour cells (CTCs), which are potentially the most lethal type of cancer cell, and may be a key component of the metastatic cascade. The clinical utility of CTCs (the "Good"), includes their diagnostic, prognostic, and therapeutic potential. Conversely, their complex biology (the "Bad"), including the existence of CD45+/EpCAM+ CTCs, adds insult to injury regarding their isolation and identification, which in turn hampers their clinical translation. CTCs are capable of forming microemboli composed of both non-discrete phenotypic populations such as mesenchymal CTCs and homotypic and heterotypic clusters which are poised to interact with other cells in the circulation, including immune cells and platelets, which may increase their malignant potential. These microemboli (the "Ugly") represent a prognostically important CTC subset, however, phenotypic EMT/MET gradients bring additional complexities to an already challenging situation.Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.